NT5E

Across TCGA pan-cancer cohorts, NT5E mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated NT5E data layer compared with 24 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher NT5E mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated NT5E expression acts as an unfavorable survival marker, although some lineages such as GBM and HNSC show a favorable association.

PDAC, LSCC, and UCEC are the cancer types where NT5E mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	All	0.297	0.515	<.001	105	view →
LSCC	DFS	Median	All	0.876	0.992	.001	31	view →
UCEC	DFS	Median	II,III,IV	0.520	0.880	.034	8	view →
GBM	OS	Tertile	All	0.649	0.352	.004	7	view →
LUAD	DFS	Quartile	III,IV	0.259	0.723	.034	4	view →
HNSC	DFS	Tertile	III,IV	1.000	0.916	.038	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

NT5E–PDAC (DFS)

Open the PDAC breakdown →